>10 g/dL; men, >12 g/dL), moderate (hemoglobin: women, 7-9.9 g/dL; men, 9-11.9 g/dL), and severe (hemoglobin: women, <7 g/dL; men, <9 g/ dL) anemia. Multivariate logistic and Cox regression analyses were implemented to evaluate 30-day mortality and primary patency (PP) at 1 year, respectively.
Fig. Logistic regression analysis of 30-day mortality in hemodialysis (HD) patients with normal-mild vs moderate vs severe anemia. AVF, Arteriovenous fistula; AVG, arteriovenous graft; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease. Objective: Nearly 100,000 people in the United States initiate hemodialysis (HD) each year. Previous studies have shown that beginning HD with an HD catheter (HC) is associated with worse mortality than with an arteriovenous fistula (AVF) or arteriovenous graft (AVG). We hypothesized that transplant wait listing would modify the effect of HD access types on mortality, given wait list candidates' better access to health care and more robust health status.
Methods: Using the U.S. Renal Data System, we studied all patients with incident end-stage renal disease who initiated HD between 2010 and 2015 with an AVF, AVG, or HC. We excluded patients who had been on HD before January 1, 2010, and patients who did not have Centers for Medicare and Medicaid Services Form 2728 data available. We used Cox proportional hazards models to study the association between HD access and mortality, including an interaction term to examine effect modification of HD access on mortality by wait list status. As a sensitivity analysis, we used doubly robust Cox proportional hazards models with 1:1 matching by propensity to be wait listed to examine effect modification of HD access on mortality by wait list status.
Results: There were 587,607 patients who newly initiated HD, of whom 87,876 (15.0%) were wait listed for kidney transplantation (Table) . Only 30,513 (5.2%) were transplanted. Transplant wait listing attenuated the association between HD access type and mortality (interaction P < .001 for both AVF and AVG vs HC). Among patients who were on the wait list, those with an AVF had a 9.3% lower risk of mortality compared with HC (adjusted hazard ratio [aHR], 0.91; 95% confidence interval [CI], 0.87-0.95), whereas those with an AVG had no difference in mortality (aHR, 0.96; 95% CI, 0.86-1.08; Fig) . Among patients not on the wait list,
